
    
      Compared with placebo, drotrecogin alfa (activated) reduces 28-day all-cause mortality in
      adult patients with severe sepsis at low risk of death (for example, with an Acute Physiology
      and Chronic Health Evaluation II (APACHE II) score <25 or single organ dysfunction).
    
  